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ORIGINAL ARTICLE
Mesenchymal stem cells from Shwachman–Diamond syndrome
patients display normal functions and do not contribute to
hematological defects
V Andre´1, D Longoni2, S Bresolin3, C Cappuzzello1, E Dander1, M Galbiati1, C Bugarin1, A Di Meglio4, E Nicolis5, E Maserati6, M Serafini7,
AJ Warren8, G te Kronnie3, G Cazzaniga1, L Sainati4, M Cipolli5, A Biondi2,9 and G D’Amico1,9
Shwachman–Diamond syndrome (SDS) is a rare inherited disorder characterized by bone marrow (BM) dysfunction and exocrine
pancreatic insufﬁciency. SDS patients have an increased risk for myelodisplastic syndrome and acute myeloid leukemia.
Mesenchymal stem cells (MSCs) are the key component of the hematopoietic microenvironment and are relevant in inducing
genetic mutations leading to leukemia. However, their role in SDS is still unexplored. We demonstrated that morphology, growth
kinetics and expression of surface markers of MSCs from SDS patients (SDS-MSCs) were similar to normal MSCs. Moreover,
SDS-MSCs were able to differentiate into mesengenic lineages and to inhibit the proliferation of mitogen-activated lymphocytes.
We demonstrated in an in vitro coculture system that SDS-MSCs, signiﬁcantly inhibited neutrophil apoptosis probably through
interleukin-6 production. In a long-term coculture with CD34þ -sorted cells, SDS-MSCs were able to sustain CD34þ cells survival and
to preserve their stemness. Finally, SDS-MSCs had normal karyotype and did not show any chromosomal abnormality observed in
the hematological components of the BM of SDS patients. Despite their pivotal role in the hematopoietic stem cell niche, our data
suggest that MSC themselves do not seem to be responsible for the hematological defects typical of SDS patients.
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INTRODUCTION
Shwachman–Diamond syndrome (SDS) is a rare autosomal
recessive inherited disorder characterized by bone marrow (BM)
dysfunction and exocrine pancreatic insufﬁciency. In almost all
affected patients, the disorder is characterized by a broad range of
additional clinical features, including hematological alteration,
with neutropenia as the most common deﬁciency, frequently
associated with anemia, thrombocytopenia, defects in the
lymphoid lineage, increased levels of fetal hemoglobin and
aplasia. Development of the latter disorder suggests that the
hematopoietic defect may arise at the level of an early
hematopoietic stem cell (HSC) or in the BM stroma. In addition,
similarly to other marrow failure syndromes, SDS patients show an
increased risk of myelodisplastic syndrome (MDS) and malignant
transformation, in particular to acute myeloid leukemia. Although
SDS represents an important model for understanding genetic
determinants in hematopoiesis and in developmental biology, the
mechanisms underlying the BM dysfunction observed in SDS is
not fully understood. In 1999, Dror and Freedman1 reported a
general marrow defects in SDS patients with abnormal BM stroma
in terms of ability to produce fat clusters and to support and
maintain hematopoiesis.
The key component of BM stroma are mesenchymal stem cells
(MSCs), which represent the pivotal organizers for the generation,
maintenance and plasticity of the HSC niche by supporting the
proliferation and differentiation of HSCs and their progenies. MSCs
generate a number of stromal cells, which have been shown to
have an impact on HSC behavior, including adipocytes,2 pre-
osteoblast,3 osteoblasts and chondrocytes.4 The hematopoietic
microenvironment controls the formation of blood cells through
the release of cytokines and extracellular matrix molecules.
Recently, Raaijmakers et al.5 demonstrated that targeted
deletion of miRNA processing endonuclease Dicer1 in
osteoprogenitor cells in the BM could induce complex
secondary changes in the organization of the hematopoietic
lineages, including the development of independent genetic
mutations and frank leukemia. This model, for the ﬁrst time,
candidates MSCs as new actors in the multi-hit process of
oncogenesis, as an expression of the involvement of
hematopoietic microenvironment in the pathophysiology of the
disease. Several studies demonstrated the presence of
chromosome alterations in MSCs derived from MDS or leukemic
patients,6,7 suggesting that unstable MSCs may facilitate the
expansion of malignant cells. Whether MSC alterations inﬂuence
hematological disorders and how such alterations contribute to
the progression of the disease remains controversial.
In this study, for the ﬁrst time, we deeply characterized MSCs
from SDS patients (SDS-MSCs) by investigating their possible
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defects in supporting hematopoiesis and their potential role in
promoting malignant transformation.
MATERIAL AND METHODS
Patients
BM samples, derived from 27 out of 80 SDS patients enrolled in the ‘SDS’
Italian registry, were collected from exceeding diagnostic specimens.
Table 1 shows the main clinical and genetic characteristics of all SDS
patients enrolled in this study. All patients were diagnosed as SDS based
on clinical criteria, including clear evidence of both hematological and
exocrine pancreatic dysfunction and were positive for the SBDS gene
mutation. The median age at enrollment was 9 years (range 1–27). All
patients did not show any tumor evidence at the time of MSC generation
and at 1 year of follow-up. The severity of neutropenia was determined
according to absolute neutrophil count (ANC) (ANC o1500¼mild
neutropenia, ANC o500¼ severe neutropenia, ANC o200¼ very severe
neutropenia). BM samples from 25 healthy donors (HDs) were obtained
from collection bags, discarded after BM infusion. Informed, written
consent approved by local ethical committee was obtained in all cases.
Isolation and culture of MSCs
Mononuclear cells were isolated from BM using Ficoll-Paque PLUS (GE
Healthcare, Waukesha, WI, USA) and seeded at 16 104 cells per cm2 in
Dulbecco’s Modiﬁed Eagle Medium low glucose (Lonza, Basel, Switzerland)
supplemented with 10% of fetal calf serum (Biosera, Ringmer, UK) at 37 1C
with 5% CO2. After 24 h, nonadherent cells were removed. Adherent cells
were trypsinized after reaching 70–80% conﬂuence, and seeded at
0.3 104 cells per cm2. MSCs were used for the experiments between
passage (P)3 and P5.
To study MSC growth pattern, adherent cells were trypsinized and
counted by 0.4% trypan blue exclusion method (dead cells were stained by
trypan blue and thus excluded) at different time points. The number of
population doubling was calculated from P2, when the cell population is
homogeneous in terms of morphology and phenotype, up to P5, with the
following formula: population doubling¼ t log 2/(logNt logN0).8
Phenotypic characterization of SDS-MSCs
To characterize expanded MSCs, the following monoclonal antibodies
were used, according to the manufacturer’s instructions: allophycocyanin-
labeled anti-CD11b (Biolegend, San Diego, CA, USA); phycoerythrin (PE)-
labeled anti-CD14 (eBioscience, San Diego, CA, USA); peridinin chlorophyll
protein-labeled anti-CD19 (Becton Dickinson (BD), Franklin Lakes, NJ, USA);
ﬂuorescein isothiocyanate-labeled anti-CD34 (IQ products, Groningen,
The Netherlands); PE-labeled anti-CD45 (BD); PE-labeled anti-CD73 (BD);
PE-labeled anti-CD90 (eBioscience); PE-labeled anti-CD105 (eBioscience);
ﬂuorescein isothiocyanate-labeled anti-HLA-ABC (BD) and PE-labeled anti-
HLA-DR (BD). Samples were acquired by FACScalibur (BD) and analyzed by
CellQuest Software (Becton Dickinson, Inc., Oakville, ON, Canada).
Multilineage differentiation
Adipogenic and osteogenic differentiating ability of MSCs was determined
at P5 as previously described.9 Brieﬂy, osteogenic differentiation was
evaluated by Alizarin Red (Sigma-Aldrich, St Louis, MO, USA) staining
and adipogenic differentiation by Oil Red O (Sigma-Aldrich) staining.
Quantitative reverse transcriptase PCR was used to determine the
expression of the following genes involved in the differentiation process:
leptin (LEP), lipoprotein lipase (LPL), peroxisome proliferator-activated
receptor gamma (PPAR-gamma), alkaline phosphatase (ALKP), osteocalcin
(OCN) and osteopontin (OPN). Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) was used as housekeeping gene. All quantitative
reverse transcriptase PCR analysis were performed on LightCycler 480
(Roche, Basel, Switzerland) using Universal Probe Library probes. Samples
were run in triplicate. Gene expression relative to GAPDH was quantiﬁed
by the 2DDCt method10 and indicated as fold change. Chondrogenic
differentiation was determined as previously described.9 Accumulation of
cartilage matrix, proteoglycans and glycosaminoglycans was evaluated by
hematoxylin-eosin and safranin/fast green staining.
Table 1. Clinical and genetic characteristic of the 27 patients enrolled in the study
Patients Sex Age at study
(years)
ANC/ml Infections SBDS mutations Karyotype
UPN1 F 7 1100 NO c.258þ 2T4C c.183_184TA4CT 46,XX
UPN2 F 3 1770 NO c.258þ 2T4C c.183_184TA4CT 46,XX[20]
UPN3 F 4 1820 NO c.258þ 2T4C c.183_184TA4CT 46,XX,i(7)(q10)[28]/46,XX[1]
UPN4 F 3 1440 NO c.258þ 2T4C c.183_184TA4CT 46,XX[7]
UPN5 F 1 260 NO c.258þ 2T4C c.183_184TA4CT 46,XY[23]
UPN6 F 8 100 NO c.258þ 2T4C c.183_184TA4CT 46,XX,i(7)(q10)[5]/46,XX[16]
UPN7 M 6 1600 URTI c.258þ 2T4C c.183_184TA4CT;c.258þ 2T4C 46,XY[15]
UPN8 F 1 260 NO c.258þ 2T4C c.183_184TA4CT;c.258þ 2T4C 46,XX[17]
UPN9 M 18 380 NO c.258þ 2T4C c.183_184TA4CT 46,XY[20]
UPN10 F 4 1100 NO c.258þ 2T4C c.183_184TA4CT 46,XY[9]
UPN11 M 4 2400 NO c.258þ 2T4C c.258þ 2T4C ND
UPN12 M 19 950 NO c.258þ 2T4C c.624þ 1G4C 46,XY[13]
UPN13 M 27 1120 NO c.258þ 2T4C c.183_184TA4CT 46,XY[20]
UPN14 F 9 1000 NO c.258þ 2T4C c.258þ 2T4C 46,XX[23]
UPN15 M 20 250 NO c.258þ 2T4C c.183_184TA4CT 46,XY[24]
UPN16 M 10 2350 NO c.258þ 2T4C c.258þ 2T4C ND
UPN17 F 6 1620 NO c.258þ 2T4C c.183_184TA4CT 46,XX[24]
UPN18 F 7 1760 ND c.258þ 2T4C c.183_184TA4CT 46,XX[22]
UPN19 M 3 2960 NO c.258þ 2T4C c.183_184TA4CT 46,XY[26]
UPN20 F 15 278 NO c.258þ 2T4C c.6524CT ND
UPN21 M 18 1500 NO c.258þ 2T4C c.183_184TA4CT 46,XY,i(7)(q10)[1]/46,XY[6]
UPN22 M 11 310 ND c.258þ 2T4C c.183_184TA4CT 46,XY,i(7)(q10)[4]/46,XY[16]
UPN23 M 13 800 ND c.258þ 2T4C c.183_184TA4CT;c.258þ 2T4C 46,XY,del(20)(q11,21q13,32)[6]/46,
XY [7](q10)[1]/46,XY[6]
UPN24 F 12 ND NO c.258þ 2T4C c.352A4G 46,XX[10]
UPN25 M 3 820 ND c.258þ 2T4C c.183_184TA4CT 46,XY[9]
UPN26 F 7 ND NO c.258þ 2T4C c.183_184TA4CT 46,XX[31]
UPN27 M 7 ND ND c.258þ 2T4C c.183_184TA4CT;c.258þ 2T4C 46,XY[17]
Abbreviations: ANC, absolute neutrophil count; F, female; M, male; ND, not detected; PB, pheripheral blood; UPN, unique patient number; URTI, upper
respiratory tract infection. All mutations are described according to the mutation nomenclature (www.hgvs.org/mutnomen).
Mesenchymal stem cells in Shwachman–Diamond syndrome
V Andre´ et al
2
Blood Cancer Journal & 2012 Macmillan Publishers Limited
Proliferation assay
Peripheral blood mononuclear cells were stimulated with 5 mg/ml of phyto-
hemagglutinin (PHA) (Irvine Scientiﬁc, Santa Ana, CA, USA) and cocultured
with different doses of irradiated (35 Gray) MSCs in 96-well plates. After
48 h of coculture cells were pulsed for 16 h with [3 H]-thymidine at 1mCi
per well (PerkinElmer, Waltham, MA, USA) and then harvested. [3 H]-
thymidine incorporation was measured using Multipurpose Scintillation
Counter (Beckman Coulter, Brea, CA, USA).
Neutrophil and MSC coculture
In order to obtain a pure and minimally activated cell population,
neutrophils were isolated from peripheral blood of HDs under endotoxin-
free conditions following the protocol described by Boyum.11 After
puriﬁcation, the mean neutrophil purity was 95%, as determined by
morphological and phenotypic analyses. Neutrophils were then layered on
MSC or cultured alone. At 24 and 48 h, cultured neutrophils were
recovered, counted and analyzed for viability by Apoptosis/Necrosis
detection kit (Enzo Life Sciences, Farmingdale, NY, USA) and ﬂow-
cytometry analysis. Supernatants from the coculture were used to
evaluate the amount of interleukin-6 (IL-6) by enzyme-linked immuno-
sorbent assay (eBioscience), according to the manufacturer’s instruction.
HSC and MSC coculture
CD34þ cells were isolated from BM of HD by anti-CD34 antibody-
conjugated magnetic beads, according to the manufacturer’s instructions
(Miltenyi Biotec, Bergisch Gladbach, Germany). CD34þ cells were
suspended in complete Roswell Park Memorial Institute medium and
plated at a density of 5 104 cells per cm2 on a conﬂuent irradiated (35
Gray) MSC layer in 48-well plate. Phenotype and short-time colony assay of
CD34þ cells were assessed weekly. A total of 103 cells were resuspended
in Iscoves Modiﬁed Dulbecco’s Media (Euroclone, Pero, Italy) and plated in
10% methylcellulose-based medium (STEMCELL Technologies, Vancouver,
BC, Canada) supplemented with 1% of pen-strep, L-glutamine, 2 U of
erythropoietin (Roche) and 10% 5637 conditioned medium. The condi-
tioned medium from 5637 tumor cell line was used as a source of colony-
stimulating factor at a ﬁnal concentration of 10%. After 21 days of incubation
at 37 1C in a fully humidiﬁed atmosphere of 5% CO2, colony-forming unit
were scored under an inverted microscope. Aggregates of450 cells were
evaluated as colonies.
Western blot analysis
MSCs (1.5 106) were collected at P5 and were lysed in radioimmuno-
precipitation assay buffer as already described.12 A total of 50mg of protein
was loaded per lane on a 10% sodium dodecyl sulfate-polyacrylamide gel.
Proteins were then transferred to a nitrocellulose membrane (Life Techno-
logies, Paisley, UK). The following antibodies were used: goat polyclonal
anti-SBDS (1/800) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
mouse monoclonal anti-b-actin (loading control, 1/20000) (Sigma-Aldrich)
in PBST/5% of milk.
Karyotype and ﬂuorescence in situ hybridization (FISH) analysis of
SDS-MSCs
MSCs were cultured in medium supplemented with 10ml/ml of colcemid
(10 g/ml, Sigma) for up to 6 h. Conventional cytogenetics was performed
by the standard procedures and QFQ (Q-bands by ﬂuorescence using
quinacrine) banding. The karyotypes were described according to the
International System for Human Cytogenetic Nomenclature (2009).13 FISH
analysis was performed on MSCs using LSI D20S108 probe (Vysis, Downers
Grove, IL, USA) and D7S486/CEP7 FISH Probe Kit (Vysis) and on BM patients
using D7S486/CEP7 FISH Probe Kit (Vysis) and BAC RP11-17F3 (20q12). The
FISH cut-off for each probe was determined analyzing MSCs derived from
HDs. The probes cut-off level was 6% for LSI D20S108 and 2% for D7S486/
CEP7. At least 200 nuclei were analyzed for each case using Isis software
(v.5.4.9; MetaSystems, Altlussheim, Germany) and Imager Z1 (Zeiss, Oberkocken,
Germany) epiﬂuorescence microscope equipped with 4’,6-diamidino-2-
phenylindole, ﬂuorescein isothiocyanate and TEXAS RED ﬁlters.
Statistical analysis
All values are expressed as mean±s.d. or s.e. To evaluate statistical
signiﬁcance between the groups, Student’s t-test was used. A P-value
o0.05 was considered to be statistically signiﬁcant.
RESULTS
Evaluation of MSC-typical features in cells expanded from BM of
SDS patients
MSCs were obtained from BM of 27 SDS patients and were
characterized for their proliferating ability, antigen expression and
differentiation into mesengenic lineages. SDS-MSCs displayed a
typical ﬁbroblast-like morphology, similarly to HD-MSCs (data not
shown). Flow-cytometric analysis showed that SDS-MSCs, as well
as HD-MSCs, were negative for hematopoietic (for example, CD34,
CD45 and MHC class II), lymphoid (for example, CD19) and
myeloid (for example, CD11b and MHC class II) markers and
positive for stromal cell-associated markers (for example, CD73,
CD90 and CD105) (Figure 1a). Adipocytic, osteoblastic and
chondrocytic differentiation assays were performed for SDS-MSCs.
SDS-MSCs were able to differentiate into osteoblasts, as demon-
strated by the histological detection of calcium deposition by
Alizarin Red staining (Figure 1b, on the left). Osteogenic
differentiation was also conﬁrmed by real-time PCR, under
osteogenic permissive condition at day 14 of culture. Expression
of ALKP, OCN and OPN osteogenic genes resulted similar in SDS-
MSCs and HD-MSCs (Supplementary Figure 1A). In addition, SDS-
MSCs were able to differentiate into adipocytes, as revealed by the
formation of lipid droplets visualized by Oil Red O staining
(Figure 1b, in the middle). Similarly to HD-MSCs, SDS-MSCs
increased the expression of PPAR-g, LEP and LPL during the
adipogenic differentiation process (Supplementary Figure 1B).
Concerning the chondrogenic differentiation, cultured pellets
became free-ﬂoating within the ﬁrst 24 h of induction. During
the differentiation process, biosynthesis and deposition of
extracellular matrix components, such as sulfated proteoglycans,
contributed to increase cell pellet size, as demonstrated by
hematoxylin-eosin (Figure 1b, on the right), safranin and fast
green staining (inner panel).
To evaluate their proliferating ability, SDS-MSCs were sub-
cultured when they reached 70–80% of conﬂuence and popula-
tion doubling time was calculated at each passage from P2 to P5.
Proliferation rate was comparable at each time point considered
(Student’s t-test 40.05) between SDS- and HD-MSCs (Figure 1c).
Interestingly, cell passaging reduced the proliferation rate in all
MSCs tested. In particular, 4 days (±1.2 for SDS-MSCs and ±1.4
for HD-MSCs) were necessary to double cell number of both
SDS-MSCs and HD-MSCs at P2, whereas population doubling
was 4.3±1.4 days for SDS-MSCs and 3.7±0.9 days for HD-MSCs
at P5.
We then evaluated the immunoregulatory activity of SDS-MSCs
by assessing their ability to inhibit lymphocyte proliferation
induced by mitogenic stimuli (that is, PHA). Peripheral blood
mononuclear cells from HD were stimulated with PHA in the
presence or absence of various concentrations of irradiated MSCs.
SDS-MSCs were able to strongly suppress lymphocyte proliferation
in a dose-dependent manner, with a 58% of inhibition observed
at 1:32 SDS-MSC/peripheral blood mononuclear cell ratio (range,
24–99%), similarly to HD-MSCs (Figure 1d).
Functional characterization of SDS-MSCs
With the aim to evaluate the functional properties of SDS-MSCs,
we analyzed their capability to preserve neutrophils from
apoptosis and to maintain the viability of CD34þ cells. Neutrophils
are very sensitive cells and once released from the BM they
circulate in the peripheral blood with a short half-life. We
investigated the effects of MSCs on spontaneous neutrophil
apoptosis, by culturing HD neutrophils in the absence or presence
of SDS-MSCs. Because Raffaghello et al.14 demonstrated that
inhibition of neutrophil apoptosis occurred at a MSC:neutrophil
ratio ranging from 1:1 to 1:500, we used a MSC:neutrophil ratio
lower than 1:50 for all the coculture experiments. As shown in
Figure 2a, after 24 h only 3% of neutrophils cultured with medium
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alone resulted viable. This percentage further decreased after 48 h
of culture to 1% of viable cells. In contrast, HD-MSCs and SDS-
MSCs were comparably able to support the viability of neutrophils
at both 24 and 48 h (Figure 2a). In particular, at 24 h, 7.6% (range
3–16%) and 13% (range 4–23%) of neutrophils were alive (double
negative cells) when cocultured with HD-MSCs or SDS-MSCs,
respectively. It has been demonstrated that IL-6 is constitutively
produced by MSCs and has a crucial role in inhibiting neutrophil-
programmed cell death. For this reason, we evaluated IL-6
concentration in supernatants recovered from SDS-MSCs and
neutrophil coculture. SDS-MSCs were able to produce IL-6 in a
time-dependent manner (Figure 2b). In particular, IL-6 production
increased after 72 h of culture with both SDS- and HD-MSCs, with
no statistically signiﬁcant differences between the two groups.
In order to assess the ability of SDS-MSCs to support and
maintain hematopoiesis, we took advantage of long-term cultures
to mimic the interactions between the hematopoietic progenitors
and the microenvironment of the BM stem cell niche in vitro. With
this aim, CD34þ -sorted cells were cocultured with MSCs from
both patients and controls. Total number of nonadherent cells was
calculated during the ﬁrst 3 weeks of coculture and was found to be
similar. After an initial decline at day 7, the total number increased
after 14 days of coculture (Figure 3a). As expected, after 21 days,
the percentage of CD34þ cells diminished up to 20% (Figure 3b).
Importantly, SDS-MSCs as well as HD-MSCs were able to preserve
the stemness of recovered cells, as evaluated by their ability to
form CFU-GM (colony forming unit-granulocyte/macrophage) colonies
in methylcellulose. No statistical differences in the number of CFU-GM
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Figure 1. Isolation and expansion of SDS-MSCs. MSCs were isolated from bone marrow of SDS patients and cultured in Dulbecco’s Modified
Eagle Medium with 10% of fetal calf serum. (a) Fluorescence-activated cell sorting (FACS) analysis of SDS-MSCs. Isotype control staining (white
area under continuous line) versus the specific antibody staining profile (gray area) is shown. Histograms from 1 representative experiment
out of 27 performed are shown. (b) Mesengenic differentiation of SDS-MSCs. To detect the osteogenic differentiation, cells were stained for
calcium deposition with Alizarin Red (on the left) and adipogenic differentiation was evaluated through the morphological appearance of fat
droplets with Oil Red O (in the middle). Cell pellet was treated with chondrogenic medium for 21 days, sections of cell pellet were stained with
hematoxylin-eoxin (on the right) and Safranin O (inner panel), which binds proteoglycans and glycosaminoglycans. Canon PowerShot G5,
magnification  10. One experiment out of twenty-seven performed is shown. (c) Expansion curve of SDS-MSCs. The graph represents the
mean±s.e. of 25 HD-SDS versus 27 SDS-MSC. Population doubling (PD)¼ t log 2/(logNt-logN0), where t represents culture time, N0 and Nt
represent cell number before and after seeding, respectively. (d) Lymphocyte proliferation in the presence or absence of SDS-MSCs. Peripheral
blood mononuclear cells (PBMCs) were stimulated with PHA in the absence ( ) or presence of different concentration of MSCs in 96-well
plates. After 48 h, cells were pulsed for 16 h with [3H]-thymidine at 1 mCi per well (PerkinElmer) and then harvested. The graph represents the
mean±s.e. of eight experiments (**Po0.01 and *Po0.05, versus PBMC stimulated with PHA in absence of MSC).
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colonies (Figure 3c) obtained from CD34þ cells cocultured with
both SDS-MSCs and HD-MSCs were observed.
Analysis of SBDS protein in SDS-MSCs
It has been demonstrated that SBDS protein shows low expression
levels in all hematopoietic cell lineages from SDS patients.15 In
order to assess the level of SBDS protein in SDS-MSCs, we
performed western blot analysis on lysates from seven SDS-MSCs
and eight HD-MSCs. In line with previous studies on BM,15 SBDS
protein was undetectable in all SDS-MSCs (lanes 1–3, Figure 4).
On the contrary, a variable amount of protein was detected in
HD-MSC (lanes 4–8).
Karyotype and FISH analysis of SDS-MSCs
To study the potential role of MSCs in the predisposition to
leukemia or MDS of SDS patients, we focused on the cytogenetic
characterization of SDS-MSCs. With this aim, we performed
conventional cytogenetic and FISH analysis to explore genomic
alterations in MSCs obtained from 4 out of 5 patients carrying
chromosomal abnormalities, and to compare these with the
aberrations observed in the BM of the same patients.
Karyotype and FISH analysis were performed in SDS-MSCs
obtained from UPN3, UPN6, UPN21 and UPN23, in the BM sample
and in MSCs from ﬁve healthy volunteers. The median number of
MSC passages was 5. The culture time ranged from 29 to 35 days.
FISH analysis demonstrated that in none of the patients, SDS-
MSCs displayed the chromosomal abnormality (n¼ 0/200 nuclei
analyzed) observed in the respective BM sample (UPN3: i(7)(q10),
n¼ 124/200; UPN6: i(7)(q10), n¼ 49/549; UPN21: i(7)(q10), n¼ 30/
300 and UPN23: del(20)(q11), n¼ 162/601). Figure 5a shows the
FISH analysis of a representative experiment.
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Figure 2. (a) Evaluation of neutrophil viability cultured with SDS-
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of HD-MSCs and SDS-MSCs at 24 and 48h. Viable neutrophils were
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time point analyzed. The mean percentage of viable cells evaluated
in 10 independent experiments is shown. (b) IL-6 secretion after
neutrophils and SDS-MSCs coculture. Quantification of IL-6 in the
supernatants was detected by enzyme-linked immunosorbent assay
at different time points. The graph represents the mean±s.e. of 10
experiments (Student’s t-test 40.05).
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Figure 3. (a) Nonadherent cell numbers from long-term culture with
SDS-MSCs. In all, 5 104 CD34þ cells from HDs were plated in wells
containing irradiated MSCs (dotted line). Cells were harvested from
individual wells after 7, 14 and 21 days. Data represent the mean of
eight experiments performed±s.e., Student’s t-test 40.05. (b) FACS
analysis of nonadherent cells obtained after long-term culture.
Percentage of CD34þ cells from HD-MSCs or SDS-MSCs cocultures
was shown. The experiment is representative of eight performed.
(c) Number of CFU-GM derived from long-term culture nonadherent
cells, plated weekly in short-term clonogenic assays. After 7, 14 and
21 days of coculture, 1000 of nonadherent cells were seeded in wells
containing methylcellulose. Colonies were scored as CFU-GM using
an inverted microscope after 21 days. Data represent the mean of
eight experiments performed±s.e. (Student’s t-test 40.05).
Mesenchymal stem cells in Shwachman–Diamond syndrome
V Andre´ et al
5
& 2012 Macmillan Publishers Limited Blood Cancer Journal
Cytogenetic analysis of SDS-MSCs (20 metaphases in all cases)
did not show any of the chromosomal alterations observed in the
BM (UPN3: i(7)(q10), n¼ 28/29; UPN6: i(7)(q10), n¼ 5/21; UPN21:
i(7)(q10), n¼ 1/7; and UPN23: del(20)(q11), n¼ 6/13) (Table 1). No
other abnormalities, aneuploidy or polyploidy were observed in
SDS-MSCs. Chromosome analysis of HD-MSCs showed normal
diploid karyotype, with no aneuploidy, polyploidy or structural
abnormalities (data not shown).
DISCUSSION
SDS is an autosomal recessive disorder characterized by hemato-
logical defects, exocrine pancreatic insufﬁciency and skeletal
deformities. Patients may display a wide range of hematological
abnormalities, but the number of neutrophils in peripheral blood
samples is reduced (neutropenia) in all individuals affected. Using
long-term cultures of marrow stromal cells from SDS and
unaffected subjects, Dror and Freedman1 demonstrated that
patients show dysfunction of the BM stroma. In particular, a
reduced ability to support and maintain hematopoiesis and a stem
cell defect were observed. Until now, the role of MSCs in the
pathophysiology of the inefﬁcient hematopoiesis observed in SDS
is still unclear.
In the present study, we isolated and characterized MSCs from
the BM of 27 patients. We demonstrated that SDS-MSCs are similar
to HD-MSCs in terms of morphology and growth kinetics.
Furthermore, ﬂow-cytometry data demonstrated the expression
of several cell-surface antigens, such as CD73, CD90 and CD105,
commonly found on HD-MSCs. Moreover, SDS-MSCs were able
to differentiate into adipocytes, osteoblasts and chondrocytes,
under appropriate induction conditions. Finally, we demonstrated
that SDS-MSCs strongly inhibit the proliferation of PHA-activated
lymphocytes. Overall, these results demonstrated that cells with
typical MSC features can be successfully obtained from the BM of
SDS patients.
After characterizing SDS-MSCs, we tried to better understand
their potential role in the hematopoietic insufﬁciency observed in
SDS patients. Stromal impairment in SDS can be related to either
the reduced expression of hematopoietic cytokines, the altered
production of extracellular matrix or the abnormal expression of
adhesion molecules necessary for the interaction between
hematopoietic progenitors and stromal cells. We cocultured
SDS-MSCs with CD34þ cells and, in our culture condition, we
observed that SDS-MSCs were able to support the viability and the
stemness potential of CD34þ cells as well as HD-MSCs. The altered
function of SDS stroma reported by Dror1 was demonstrated by
in vitro experiments using BM stroma in toto as an integral unit of
various cell types. In our experiments, we used isolated MSCs as
precursors of a number of stromal cells, which have been shown
to have an impact on HSC behavior. Despite their essential role in
organizing and maintaining the HSC niche, our data suggest that
MSCs themselves do not seem to be responsible for the BM failure
typical of SDS.
We also analyzed the effect of SDS-MSCs on neutrophils and we
demonstrated that, after coculture, neutrophils were protected
from apoptosis. As demonstrated by Raffaghello et al.13 for normal
MSCs, SDS-MSCs produced IL-6, a cytokine involved in prevention
of excessive or inappropriate neutrophil activation. Overall, these
results indicate that SDS-MSCs act in vitro just like their normal
counterparts. Further in vivo studies mirroring the whole
architecture of the HSC niche are needed to comprehend the
possible MSC defects in SDS patients.
Patients analyzed in our study were diagnosed with SDS based
on clinical criteria and the diagnosis was supplemented by
positive SBDS gene mutation tests. In agreement with previous
reports, the 258þ 2T4C and 183-1844CT mutations were the
most common in our cohort. Woloszynek et al.16 detected the
SBDS protein in samples from family members with normal SBDS
alleles but not in patients. Full-length SBDS protein was not
detected in leukocytes of SDS patients with the most common
SBDS mutations, consistent with a loss-of-function mechanism. We
demonstrated that, even though SBDS gene transcript expression
did not differ signiﬁcantly between patients and controls (data not
shown), SBDS protein was not detectable in SDS-MSCs. Recent
studies in yeast and patient BM cells show that SBDS gene is
involved in RNA metabolism and ribosome biogenesis.17,18 SBDS
is an essential gene in embryogenesis and it is also implicated in
cell division and cellular stress response.19,20 Further studies are
needed to better comprehend the mechanisms compensating the
absence of SBDS protein.
Similar to other marrow failure syndromes, SDS patients are
cancer prone and have a risk of developing myelodysplastic
syndrome and/or leukemia. Raaijmakers et al.,5 using transgenic
mice, showed that genetic alteration of cells belonging to the
BM microenvironment can induce MDS with ineffective
hematopoiesis and with occasional transformation to acute
myeloid leukemia. Although it is generally agreed that the
marrow microenvironment has a role in the biology of
hematological diseases, the mechanisms by which the stromal
1 2 3 4 5 6 7 8
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43 kDa
Figure 4. Detection of SBDS protein in SDS-MSCs by western blot.
Proteins extracted from MSCs were analyzed by immunoblotting
with the SBDS antiserum. b-actin protein level served as a loading
control. SBDS protein is absent in SDS-MSCs. Shwachman patients
are lanes 1, 2 and 3 (UPN16, UPN1 and UPN11, respectively); controls
are lanes 4, 5, 6, 7 and 8. Molecular size markers are indicated on the
left in kilodaltons.
BM MSC
UPN 3
UPN 23
CEP7
D7S486
CEP7
D7S486
RP11-17F3 D20S108
Figure 5. (a) FISH analysis performed on SDS-MSCs. The LSI D7S486/
CEP7 (Vysis) and BAC RP11-17F3 probes were used to search for
isochromosome 7q and 20q arm deletion in BM samples: UPN3
showed hybridization pattern consistent with the presence of
isochromosome 7q (two green signals and three red signals); UPN23
revealed deletion of 20q (one aqua signal). SDS-MSCs derived from
patients were tested for the same abnormalities using LSI D7S486/
CEP7 (Vysis) and LSI D20S108 (Vysis) probes, and they did not reveal
any aberrations.
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compartment promote the malignant transformation is unclear.
Different groups6,7,21–24 have shown the extensive variability of
the aberrations, such as balanced and unbalanced translocations,
hypodiploidy, deletions and whole-chromosome gains in MSCs
obtained from leukemic patients. In view of these data, genetic
alterations in MSCs may indicate a common origin and a potential
interaction of MSCs in leukemia development and/or progression.
To study the potential implication of MSCs in predisposing or
promoting leukemia or MDS evolution in SDS patients, we
analyzed their genetic features. In spite of having chromosomal
abnormalities in the BM counterpart, we did not ﬁnd any
chromosomal alteration in SDS-MSCs. Probably, the most
common chromosomal alterations [i(7)(q10) or del(20)(q11)]
observed in SDS patients occurred in a more mature, already
committed, progenitor instead of involving the mesenchymal
compartment. The fact that SDS-MSC did not carry the same
anomaly observed in the BM of patients does not exclude the
presence of other genetic alteration; however, whole-genome
single-nucleotide polymorphism array did not show any copy
number aberration in MSC from the SDS patient tested. These
results suggest that SDS-MSCs patients may be nonmalignant cells.
All SDS patients did not show any tumor evidence at the time of
MSC generation and in 1 year follow-up. It would be of interest to
continuously follow the patients and, in case of tumor evolution,
evaluate the MSC genetic status at the time and early before the
progression.
We described, for the ﬁrst time at our knowledge, the isolation,
expansion and functional characterization of SDS-MSCs. Our
results showed that SDS-MSCs were similar to normal BM-derived
MSCs in terms of morphology, growth property, surface epitopes
and differentiation ability. Moreover, SDS-MSCs had normal
karyotype and may be nonmalignant. Despite their pivotal role
in the BM niche, our data suggest that MSC themselves do not
seem to be responsible for the hematological defects typical of
SDS patients. Our data give a new insight into biology of SDS and
might have a positive impact of the management of HSC
transplantation in SDS patients, by sustaining HSC transplantation
despite the supposed risk of failure due to stroma abnormalities.
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